Prof dr Guus van Dongen has a background in biochemistry with focus on the development and characterization of targeted drugs like monoclonal antibodies (mAbs), nanobodies and tyrosine kinase inhibitors (TKIs). In this field he introduced “immuno-PET” and “TKI-PET”, the PET imaging of radiolabeled mAbs and TKIs, respectively. Initially, the focus was especially on oncology, nowadays all disease areas are covered. After being professor at the Dept of Otolaryngology/Head-and-Neck-Surgery VUmc since 2003, he became professor at the Dept of Radiology & Nuclear Medicine VUmc in 2012. He became founder and managing director of the Amsterdam UMC Imaging Center (opened 2019), a center housing all preclinical and clinical imaging facilities and focusing on imaging in drug development. He has brought > 30 antibody conjugates and other biopharmaceuticals in first-in-human studies. He is (co)author of  >250 papers in peer-reviewed journals, inventor at several patents, and has many collaborations with (inter)national biotech, pharma and imaging companies. In 2023 he received the Amsterdam Impact Award. After his retirement in 2023 he remained active at some Amsterdam UMC initiatives (e.g. the FORESIGHT initiative, a Dutch consortium that exists of UMCG, AvL, AUMC and TU/e and which is specialized in molecular imaging in drug development and applications). In addition, he became CSO of LinXis Biopharmaceuticals, a company developing Fibrobody®-Tracer Conjugates and Fibrobody® Drug Conjugates for diagnosis and therapy of fibrosis.